Compare YSXT & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | NSPR |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | China | United States |
| Employees | 39 | N/A |
| Industry | Automotive Aftermarket | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 33.7M |
| IPO Year | N/A | 2009 |
| Metric | YSXT | NSPR |
|---|---|---|
| Price | $1.04 | $0.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 17.1K | ★ 116.6K |
| Earning Date | 02-03-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $0.63 |
| 52 Week High | $5.96 | $2.93 |
| Indicator | YSXT | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 41.88 |
| Support Level | $1.03 | $0.69 |
| Resistance Level | $1.28 | $1.04 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 12.50 | 66.67 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.